Conversely, an improvement in ORR and OS for immunotherapy over the anti-vascular agent was reported independently from the tumor PD-L1 expression level, even though the magnitude of benefit was higher in patients with PD-L1 ≥1% (13). This evidence concerns the gene CD274 and neoplasm.